Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project

Astrid S. Doorduijn 1,2,*, Marjolein Visser 3*, Ondine van de Rest 4*, Maartje I. Kester 2, Francisca A. de Leeuw 2,3, Sanne Boesveldt 4, Jay L. P. Fieldhouse 2, Ellen G. H. M. van den Heuvel 6*, Charlotte E. Teunissen 5, Philip Scheltens 2*, Wiesje M. van der Flier 2* and Marian A. E. de van der Schueren 1,2

1 Department of Nutrition and Dietetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, 1081HV Amsterdam, The Netherlands; m.devanderschueren@amsterdamumc.nl
2 Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081HZ Amsterdam, The Netherlands; m.kester@vumc.nl (M.I.K.); f.deleeuw@vumc.nl (F.A.d.L.); j.fieldhouse@vumc.nl (J.L.P.F.); p.scheltens@vumc.nl (P.S.); wm.vdflier@vumc.nl (W.M.v.d.F.)
3 Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam and the Amsterdam Public Health Research Institute, 1081HV Amsterdam, The Netherlands; m.visser@vu.nl
4 Division of Human Nutrition and Health, Wageningen University & Research, 6708WE Wageningen, The Netherlands; ondine.vanderest@wur.nl (O.v.d.R.); sanne.boesveldt@wur.nl (S.B.)
5 Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081HZ Amsterdam, The Netherlands; c.teunissen@vumc.nl
6 FrieslandCampina, 3818LE Amersfoort, The Netherlands; ellen.vandenheuvel@frieslandcampina.com
7 Department of Nutrition and Health, HAN University of Applied Sciences, 6525EJ Nijmegen, The Netherlands
* Correspondence: a.doorduijn@amsterdamumc.nl; Tel.: +31-20-4444501

Received: 9 May 2019; Accepted: 21 May 2019; Published: 23 May 2019

Abstract: As malnutrition is common in patients with Alzheimer’s disease (AD), we evaluated nutritional status and body composition of patients with AD, mild cognitive impairment (MCI) and controls, and studied associations of AD biomarkers and cognitive performance with nutritional status and body composition. We included 552 participants, of which 198 patients had AD, 135 patients had MCI and 219 controls. We assessed nutritional status (mini nutritional assessment (MNA)) and body composition (body mass index (BMI), fat-free mass (FFM) and waist circumference). Linear regression analyses (adjusted for age, gender and education where appropriate) were applied to test associations of AD biomarkers and cognitive performance on five domains with nutritional parameters (dependent). Patients with MCI and AD had a lower BMI and MNA score than controls. Worse performance in all cognitive domains was associated with lower MNA score, but not with body composition. AD biomarkers were associated with MNA score, BMI and waist circumference, and associations with MNA score remained after adjustment for cognitive performance. Both AD biomarkers and cognitive performance were associated with nutritional status, associations with AD biomarkers remained after adjustment for cognition. Our data suggest that malnutrition is not only related to impaired cognition but also to AD pathology.

Keywords: Alzheimer’s disease; mild cognitive impairment; subjective cognitive decline; malnutrition; older adults; body composition
1. Introduction

Unintended weight loss and protein energy malnutrition are common features in patients with moderate to severe Alzheimer’s disease (AD) dementia. The prevalence of malnutrition is reported to range from 0%–13% in community-dwelling patients [1,2] to 30%-60% in institutionalized patients [3,4]. Malnutrition in patients with AD is associated with an accelerated progression of disease and increased morbidity and mortality [5–7]. Much less investigated is the prevalence of malnutrition in patients with mild cognitive impairment (MCI). The few available studies showed that patients with MCI are at higher risk of malnutrition than cognitively healthy adults, albeit at lower risk than patients with AD [8–10]. Population-based studies in non-demented adults found that weight loss is a predictor for incident MCI and dementia [6,11,12], and may be one of the first signs of cognitive problems.

Several hypotheses have been proposed to explain how weight loss is associated with AD. One potential explanation is poor nutritional intake caused by a decline in cognitive functioning. Some examples are forgetting to eat, no longer being able to use eating utensils, chewing problems or dysphagia [13,14]. Second, biological changes in the brain might play a role in changes in the nutritional status of patients with AD [15]. Cerebrospinal fluid (CSF) β-amyloid 42 (Aβ42), total tau (tau) and tau phosphorylated at threonine 181 (p-tau) are considered to reflect AD pathophysiology and make it possible to measure AD pathology ‘in vivo’ [16]. AD pathology has been hypothesized to elevate metabolism and therefore energy expenditure, or to alter the uptake of nutrients leading to malnutrition [15]. It has, however, not yet been studied whether AD pathology or cognitive performance in different domains are associated with nutritional status or body composition. The aim of this study was to compare the nutritional status and body composition of patients with AD and MCI to cognitively normal controls. Furthermore, we studied associations of AD biomarkers and cognitive performance with nutritional status and body composition.

2. Materials and Methods

2.1. Study Population

The NUDAD (Nutrition, the Unrecognized Determinant in Alzheimer’s Disease) study is a prospective cohort studying nutritional determinants in AD and pre-dementia stages, with three-year clinical follow-up. Here, we present cross-sectional baseline data of all participants enrolled in NUDAD. NUDAD is a subsample of the Amsterdam Dementia Cohort, existing of patients who visited our Alzheimer center between September 2015 and August 2017 and were diagnosed with AD, MCI or subjective cognitive decline (SCD) and had a mini-mental state examination (MMSE) score >16 [17]. Patients underwent a standardized dementia screening, including extensive neuropsychological assessment, neurological examination and laboratory tests [18]. Clinical diagnosis of MCI and AD was established by consensus in a multidisciplinary meeting according to the National Institute on Aging-Alzheimer’s Association criteria [19,20]. As a control group, we used subjects with SCD who presented with memory complaints but appeared normal on all clinical examinations, i.e., criteria for MCI, dementia or psychiatric diagnosis were not fulfilled [18]. In total 552 participants were included, 198 patients with AD, 135 patients with MCI and 219 controls. Informed consent was obtained from all participants and the protocol was approved by the Ethics Committee of the Amsterdam UMC(2015.457).

Descriptive characteristics included: age, gender, MMSE score, level of education, living situation (with partner/children, alone, nursing home) and smoking status (current, former, never). Level of education was assessed using the Verhage classification system [21], which we categorized into low (score 1–3), intermediate (score 4 and 5) and high (score 6 and 7). Furthermore, the presence of diabetes mellitus, hypertension, hypercholesterolemia and the history of myocardial infarct were retrieved from medical records. Advanced glycation end product (AGE) score, a measure of cardiovascular risk, was measured via skin autofluorescence with the AGE reader [22]. Apolipoprotein E (APOE) ε4 status was dichotomized into carrier (1 or 2 ε4 alleles) or non-carrier [23]
2.2. Body Composition

Body mass index (BMI), also known as the Quetelet Index, was calculated by dividing the measured body weight by the squared measured height (kg/m\(^2\)). Participants were classified as: underweight (BMI < 18.5 kg/m\(^2\)), normal weight (BMI 18.5–24.9 kg/m\(^2\)), overweight (BMI 25–29.9 kg/m\(^2\)), or obese (BMI ≥ 30 kg/m\(^2\)). All circumferences (cm) were measured with a measuring tape in standing position: arm at the mid-upper left arm hanging loosely by the side, calf at the broadest point, waist at the smallest part between the lowest rib and the hip, and the hip at the broadest part [24]. Fat-free mass (FFM, kg) was estimated using multi-frequency bio-electrical impedance analysis (Bodystat Quadscan 4000) and the formula of Kyle [25]. The availability for body composition parameters ranged from 78% for FFM to 100% for BMI.

2.3. Nutritional Status

Nutritional status was evaluated with the Mini Nutritional Assessment (MNA) [26,27]. Scores ranged from 0 to 30 with a higher score indicating a better nutritional status. Participants were classified as: malnourished (MNA score <17), at risk of malnutrition (MNA score 17–23.5) or well-nourished (MNA score >23.5) [28]. To avoid that differences in MNA score were driven by differences in cognitive performance, we also analyzed a modified MNA score, leaving out the question about neuropsychological problems. MNA was available in 65% of our study population.

2.4. Neuropsychological Assessment

Cognitive performance was measured using a standardized neuropsychological test battery, covering five domains. The domain memory included: total recall on visual association test (VAT) and total immediate and delayed recall of the Dutch version of the Rey auditory verbal learning task [29,30]. The domain attention included: trail making test (TMT) part A, forward condition of digit span, and Stroop test word and color subtasks [31–33]. The domain executive functioning included: frontal assessment battery, backward condition of digit span, Stroop test color-word subtask and letter fluency [32–35]. The domain language included: category fluency (animal naming) and the naming condition of the VAT [29,36]. Finally, the domain visuospatial ability included: dot counting, fragmented letters and number location [37]. Raw test scores were converted into z-scores using the mean and SD of our study population. The test scores for TMT A were log-transformed because they were not normally distributed. Z-scores for TMT A and Stroop were inverted, such that lower scores indicate worse cognitive performance for all cognitive tests. Domain scores were calculated by averaging z-scores of the individual tests within that domain if at least two tests were available. Availability of the domain scores ranged from 93% for visuospatial ability to 98% for memory.

2.5. AD Biomarkers

CSF was obtained by lumbar puncture using a 25-gauge needle and collected in 10 mL polypropylene tubes (Sarstedt) following standardized protocols [38]. Aβ\(_{42}\), tau and p-tau concentrations were determined with sandwich Innotest ELISAs (Fujirebio, Ghent, Belgium) [39] and available in 393 participants (71%). Aβ\(_{42}\) concentrations were adjusted for the drift that occurred over the years [40].

2.6. Statistical Analyses

Between-diagnosis group differences in participant characteristics, nutritional status and body composition were tested using analysis of variance (ANOVA) with post-hoc LSD (least significant difference), adjusted t-test for continuous variables and chi-square-test for categorical variables. ANOVAs of nutritional status and body composition were adjusted for age, gender and education. Analyses with FFM were additionally adjusted for height and fat mass. Within the total cohort, we used linear regression analyses to evaluate associations between AD biomarkers in CSF or cognitive domains (independent variables) with nutritional status and body composition variables (dependent variables). All descriptive variables in Table 1 that changed the regression coefficient ≥ 10% were regarded as confounders and included in the
model. First, we assessed the association of AD biomarkers with nutritional parameters adjusted for age and gender (Table 3, model 1), followed by additional adjustment for all cognitive domain scores to examine the association of biomarkers independent of cognitive performance (Table 3, model 2). Similarly, the association of cognitive domains with nutritional parameters were adjusted for age, gender and education (Table 4, model 1), followed by additional adjustment for both Aβ_{42} and tau levels to examine the association of cognitive performance independent of AD biomarkers (Table 4, model 2). To test the assumptions of the regression analyses, we plotted and checked residuals of all models, which were all normally distributed. Furthermore, in each model, we checked tolerance values, variance inflation factors and correlations between variables and did not observe multicollinearity. Significance was set at \( p < 0.05 \). All analyses were performed with SPSS version 22 (released 2013, IBM SPSS Statistics for Windows, Armonk, NY, USA).

### 3. Results

Patients with MCI and AD were older, had a lower MMSE score and had a lower level of education than controls (Table 1). Groups did not differ in vascular risk factors. Patients with MCI and AD were more often APOE e4 carriers and had lower Aβ_{42} levels and higher tau and p-tau levels than controls. As expected, cognitive performance on all domains differed between groups, with controls scoring highest and patients with AD scoring lowest.

#### Table 1. Characteristics of the study population according to diagnosis group.

|                          | Controls | MCI       | AD         | \( p \)-Value |
|--------------------------|----------|-----------|------------|--------------|
| Age (years)              | 60.6 ± 7.7 | 66.3 ± 7.7 | 67.4 ± 7.9 | <0.001       |
| Gender, female           | 219/103 | 135/40.0 | 198/50.0   | 0.193        |
| MMSE score               | 219/29   | 135/25-28 | 198/21-23  | <0.001       |
| Vegetarian dietary pattern | 98 (10.2) | 53 (3.8)  | 74 (13.5)  | 0.191        |
| Level of education       |          |           |            |              |
| Low                      | 13 (5.9) | 13 (9.6)  | 17 (8.6)   | 0.014        |
| Intermediate             | 79 (36.1)| 67 (49.6) | 93 (47.0)  |              |
| High                     | 127 (58.0)| 55 (40.7)| 88 (44.4)  |              |
| Living situation         |          |           |            |              |
| With partner/children    | 163 (74.4)| 111 (82.2)| 155 (78.3)|              |
| Alone                    | 56 (25.6)| 23 (17.0)| 41 (20.7)  | 0.225        |
| Nursing home             | 0 (0)    | 1 (0.7)  | 2 (1.0)    |              |
| Smoking status           |          |           |            |              |
| Current                  | 28 (12.8)| 23 (17.0)| 26 (13.1)  |              |
| Former                   | 85 (38.8)| 52 (38.5)| 73 (36.9)  |              |
| Never                    | 106 (48.4)| 60 (44.4)| 99 (50.0)  |              |
| Vascular risk factors    |          |           |            |              |
| Diabetes Mellitus        | 219/16   | 135/18    | 198/17     | 0.151        |
| Hypertension             | 219/49   | 135/36    | 198/52     | 0.557        |
| Hypercholesterolemia     | 219/21   | 135/19    | 198/29     | 0.242        |
| Myocardial infarct       | 219/4    | 135/7     | 198/5      | 0.174        |
| AGE score                | 175/2.3  | 113/2.4   | 169/2.4    | 0.157        |
| AD biomarkers            |          |           |            |              |
| APOE e4 carrier          | 205/89   | 129/71    | 190/123    | <0.001       |
| CSF Aβ_{42} (pg/mL)      | 150/1047 | 103/856   | 141/592    | <0.001       |
| CSF tau (pg/mL)          | 149/342  | 104/516   | 141/547    | <0.001       |
| CSF p-tau (pg/mL)        | 149/52   | 103/71    | 141/92     | <0.001       |
| Cognitive domain specific z-scores | | | | |
| Memory                   | 216/0.79 | 130/-0.16 | 193/-0.76  | <0.001       |
| Attention                | 215/0.39 | 132/0.05  | 196/-0.51  | <0.001       |
| Executive functioning    | 215/0.45 | 132/0.04  | 188/-0.61  | <0.001       |
| Language                 | 215/0.43 | 129/0.08  | 190/-0.52  | <0.001       |
| Visuospatial ability     | 210/0.30 | 127/0.17  | 175/-0.47  | <0.001       |

Data in mean ± SD; n (%); median (interquartile range); AD = Alzheimer’s disease; MCI = mild cognitive impairment; MMSE = mini-mental state examination; AGE = advanced glycation endproduct; APOE = apolipoprotein E; CSF = cerebrospinal fluid; Aβ_{42} = β-amyloid 42; p-tau = phosphorylated tau; † significantly different from controls upon post-hoc testing; ‡ significantly different from MCI upon post-hoc testing.
ANCOVAs of body composition showed that patients with MCI and AD had a lower BMI, and were less likely to be obese than controls (Table 2). In addition, patients with MCI had a lower FFM, adjusted for height and fat mass, compared to patients with AD and controls. Patients with AD had a smaller waist and hip circumference compared to controls. There was no interaction with gender for any nutritional parameter. Groups did not differ in arm or calf circumference. Analyzing nutritional status, both full MNA and modified MNA score differed between groups, with patients with AD scoring lowest. Four patients with AD, one patient with MCI and one control were classified as malnourished. More participants were at risk of malnutrition, 38 patients with AD, 17 patients with MCI and 12 controls \( (p = 0.001) \).

**Table 2.** Nutritional status and body composition per diagnosis group.

|                        | Controls | MCI | AD | \( p \)-Value |
|------------------------|----------|-----|----|--------------|
| **BMI (kg/m²)**        | 219      | 135 | 198| 0.001        |
| BMI category           |          |     |    | <0.001       |
| Underweight (BMI < 18.5) | 0 (0)   | 3 (2.2) | 3 (1.5) | 0.001 |
| Normal weight (BMI 18.5–24.9) | 93 (42.5) | 58 (43.3) | 111 (56.1) | 0.001 |
| Overweight (BMI > 24.9) | 73 (33.3) | 60 (44.4) | 68 (34.3) | 0.001 |
| Obese (BMI ≥ 30)      | 53 (24.2) | 14 (10.4) | 16 (8.1) | 0.001 |
| FFM * (kg)            | 181      | 152 | 52.9 ± 0.3 | 0.001 |
| Waist circumference (cm) | 210      | 127 | 93.8 ± 0.3 | 0.024 |
| Hip circumference (cm) | 210      | 127 | 100.9 ± 0.8 | 0.000 |
| Arm circumference (cm) | 210      | 127 | 28.2 ± 0.3 | 0.068 |
| Call circumference (cm) | 210      | 127 | 35.5 ± 0.3 | 0.367 |
| MNA score             | 133      | 134 | 24.3 ± 0.2 | <0.001 |
| Modified MNA score    | 133      | 134 | 23.6 ± 0.2 | 0.050 |
| MNA category          |          |     |    | 0.001        |
| Malnourished (MNA < 17) | 1 (0.8) | 1 (1.1) | 4 (3.0) | \( \dagger \) |

Data is presented as mean ± SE; \( n \) (%); MCI = mild cognitive impairment; AD = Alzheimer’s disease; BMI = body mass index; FFM = fat-free mass, adjusted for height and fat mass; MNA = mini nutritional assessment; all tested using age, gender and education adjusted ANOVA with post-hoc LSD adjusted t-test or chi-square-test; \( \dagger \) significantly different from controls upon post-hoc testing; \( \ddagger \) significantly different from MCI upon post-hoc testing.

Adjusted linear regression analyses showed that higher levels of tau and p-tau were related to lower BMI, FFM, waist circumference and lower MNA scores. Lower \( \text{A}_β \text{42} \) levels were related to lower BMI, waist circumference and full MNA score (Table 3, model 1). In the analyses adjusted for cognitive performance, the association of both tau and p-tau with the full MNA score remained whereas the associations with \( \text{A}_β \text{42} \) lost significance (Table 3, model 2). Furthermore, the association of p-tau with the modified MNA score remained, while the association of tau with this score lost significance.

**Table 3.** Associations of AD biomarkers in CSF with nutritional status and body composition.

|                      | \( \text{A}_β \text{42} \) | Tau | P-tau |
|----------------------|---------------------------|-----|-------|
|                      | Model 1                    | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 |
| BMI (kg/m²)          | 0.16 *                    | 0.17 | 0.22 *  | 0.13 | 0.13 |
| FFM (kg)             | 0.01                       |       | 0.11   |      |
| Waist Circumference (cm) | -0.23 *               | -0.14 | -0.27 * | -0.15 | -0.13 |
| MNA Score            | -0.05 *                   | -0.14 | -0.28 * | -0.17 | -0.15 |
| Modified MNA Score   | -0.05 *                   | -0.14 | -0.28 * | -0.17 | -0.15 |

Data presented as \( \beta \) (regression coefficients); \( * p < 0.05 \); model 1 adjusted for age and gender; model 2 additionally adjusted for cognitive domain scores (memory, attention, executive functioning, language, visuospatial ability); \( \text{AD} = \text{Alzheimer’s disease}; \text{CSF} = \text{cerebrospinal fluid} ; \text{A}_β \text{42} = \text{β-amyloid 42} ; \text{p-tau} = \text{phosphorylated tau} ; \text{BMI} = \text{body mass index} ; \text{FFM} = \text{fat-free mass, adjusted for height and fat mass in both models} ; \text{MNA} = \text{mini nutritional assessment} \).

Adjusted linear regression analyses of cognitive performance revealed associations of all cognitive domains with the full MNA score, with lower domain scores being related to lower full MNA score (Table 4, model 1). Similarly, poorer performance on the domains attention, executive functioning, language and visuospatial ability, but not memory, was associated with a lower modified MNA score.
Additionally adjusted for AD biomarker levels, the association of all cognitive domain scores with full MNA score remained, while the association with the modified MNA remained for the domains executive functioning and visuospatial ability only (Table 4, model 2). There were no associations of cognitive domain scores with BMI, FFM and waist circumference.

### Table 4. Associations of cognitive domains with nutritional status and body composition.

| Cognitive Domain       | BMI (kg/m²) | FFM (kg) | Waist Circumference (cm) | MNA Score | Modified MNA Score |
|------------------------|-------------|----------|--------------------------|-----------|--------------------|
| Memory                 | Model 1     | 0.07     | 0.05                     | 0.21 *    | 0.10               |
|                        | Model 2     | 0.15     | 0.00                     | 0.05 *    | 0.00               |
| Attention              | Model 1     | 0.01     | 0.00                     | 0.19 *    | 0.12 *             |
|                        | Model 2     | 0.14     | 0.07                     | 0.12 *    | 0.07               |
| Executive functioning  | Model 1     | 0.02     | 0.02                     | 0.31 *    | 0.21 *             |
|                        | Model 2     | 0.25     | 0.15                     | 0.31 *    | 0.21 *             |
| Language               | Model 1     | −0.01    | −0.01                    | 0.18 *    | 0.11 *             |
|                        | Model 2     | −0.01    | 0.07                     | 0.32 *    | 0.12 *             |
| Visuospatial ability   | Model 1     | 0.06     | 0.07                     | 0.20 *    | 0.12 *             |
|                        | Model 2     | 0.20     | 0.13                     | 0.20 *    | 0.12 *             |

Data presented as β (regression coefficients); * p < 0.05; model 1 adjusted for age, gender and education; model 2 additionally adjusted for Aβ42 and tau levels; BMI = body mass index; FFM = fat-free mass, adjusted for height and fat mass in both models; MNA = mini nutritional assessment.

### 4. Discussion

The main finding of this study is that lower Aβ42 and higher tau and p-tau levels were associated with poorer nutritional status and body composition. Moreover, poorer cognitive performance in all domains was associated with poorer nutritional status, but not with body composition.

Consistent with the literature, patients with AD and MCI had lower BMI and smaller waist and hip circumferences than controls [9,10], while the MNA malnutrition score of patients with MCI was in between the score of controls and patients with AD [8,9,41]. We extend on existing literature by adding the modified MNA score (leaving the question on neuropsychological problems out) showing that patients with AD still scored lower, indicating that differences in MNA score cannot solely be accounted for by neuropsychological problems. These findings are strengthened by the associations of poorer performance in all cognitive domains in relation with lower MNA score, independent of AD biomarker levels. It is conceivable that patients with cognitive impairment forget to eat, which leads to malnutrition. Independent of assessment method, other studies also found that with poorer cognitive performance, the nutritional status is worse as well [42–44]. In general, older adults that live alone are at higher risk of malnutrition, however, we did not find an association of living situation with nutritional status in our population [45].

Our results also implicate a biological pathway, since more abnormal AD biomarker levels were associated with lower BMI, waist circumference and MNA score. Even after adjusting for cognitive performance, the associations with the MNA score remained, indicating that malnutrition is also directly related to AD pathology, independent of cognitive decline within AD. The biological connection between AD pathology and malnutrition might translate into an elevated metabolism, due to disease-related specific changes in lipid metabolism, and therefore a higher energy expenditure [15,46]. This needs to be confirmed in future studies in our cohort. Another possible explanation for this biological link is malabsorption of nutrients, which is supported by previous studies showing changes in the microbiome in AD [47,48], also subject for future studies. The downstream processes within the AD pathological cascade seem most important for nutritional status, since more abnormal tau and p-tau levels, but not Aβ42, were also associated with lower fat-free mass and lower modified MNA score.

Among the strengths of our study is the availability of both AD biomarkers in CSF and neuropsychological tests in different cognitive domains in a large study population covering participants from the complete AD spectrum. Furthermore, we assessed nutritional status and body composition using a set of concise and objective assessments, and not merely (self-reported) body weight or BMI. This study has some limitations. First, the MNA score was missing in 35% of the study population.
However, this percentage was similar across all diagnosis groups and there was no difference in BMI between participants with and without MNA (mean ± SD BMI participants with MNA 25.8 ± 4.1 kg/m², without MNA 26.0 ± 4.1 kg/m²; \( p = 0.498 \)) indicating the sample was representative for the study population. Second, the control group consisted of patients diagnosed with subjective cognitive decline (SCD). They visited the clinic because of memory complaints, which were not objectified by extended neuropsychological assessment. Associations might be even stronger if a control group without any cognitive complaints would have been included since persons with SCD are at increased risk of developing AD [49]. Third, we did not have data on physical activity, which might explain differences in FFM. Fourth, this study had a cross-sectional design and therefore causal inferences cannot be established. We cannot exclude that the direction of the associations is different than hypothesized and that, due to reduced dietary intake and therefore poorer nutritional status, cognitive function and biomarker levels are affected. Another option might be that AD biomarkers influence nutritional status, which in turn affects cognitive performance. We are currently following our participants longitudinally with yearly neuropyschological testing and assessment of nutritional status. These longitudinal data will enable us to further investigate the pathways involved.

In conclusion, nutritional status and body composition are poorer in patients with AD compared to controls, and already appear affected in patients with MCI. Both AD biomarkers in CSF and cognitive performance are associated with nutritional status, suggesting that malnutrition and to a lesser extent poorer body composition are not only related to impaired cognition but also directly to AD pathology. These insights advocate monitoring the nutritional status of patients with AD pathology even if they do not yet have severe cognitive impairment.

**Author Contributions:** Conceptualization, A.S.D., M.V., O.v.d.R., M.I.K., F.A.d.L., S.B., J.L.P.F., E.G.H.M.v.d.H., C.E.T., P.S., W.M.v.d.F. and M.A.E.d.v.d.S.; methodology, A.S.D., M.V., O.v.d.R. and M.A.E.d.v.d.S.; formal analysis, A.S.D., M.V. and M.A.E.d.v.d.S.; investigation, A.S.D., F.A.d.L. and J.L.P.F.; data curation, A.S.D., M.V. and M.A.E.d.v.d.S.; writing—original draft preparation, A.S.D., M.V., O.v.d.R., M.I.K., F.A.d.L., S.B., J.L.P.F., W.M.v.d.F. and M.A.E.d.v.d.S.; writing—review and editing, A.S.D., M.V., O.v.d.R., M.I.K., F.A.d.L., S.B., J.L.P.F., E.G.H.M.v.d.H., C.E.T., P.S., W.M.v.d.F. and M.A.E.d.v.d.S.; visualization, A.S.D.; supervision, M.V., O.v.d.R., P.S., W.M.v.d.F. and M.A.E.d.v.d.S.; project administration, A.S.D., M.V., O.v.d.R., M.I.K., F.A.d.L., J.L.P.F. and M.A.E.d.v.d.S.; funding acquisition, W.M.v.d.F. and M.A.E.d.v.d.S..

**Funding:** Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc fonds. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Neuroscience Amsterdam. Astrid Doorduijn, Jay Fieldhouse and Francisca de Leeuw are appointed on an NWO-FCB grant, NUDAD (project number 057-14-004).

**Acknowledgments:** We acknowledge members of the NUDAD project team: Amsterdam University Medical Center location VUmc: Wieke van der Flier, Maartje Kester, Philip Scheltens, Charlotte Teunissen, Marian de van der Schueren, Francien de Leeuw, Astrid Doorduijn, Jay Fieldhouse, Jos Overbeek, Els Dekkers; Vrije Universiteit Amsterdam: Marjolein Visser; Wageningen University & Research: Onlide van de Rest, Sanne Boesveldt; DSM: Peter van-Dael, Manfred Eggersdorfer; Nutricia Research: John Sijben, Nick van Wijk, Amos Attali, J. Martin Verkuyl; FrieslandCampina: Martijn Veltkamp, Ellen van den Heuvel.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Droogsma, E.; Van Asselt, D.; Scholzel-Dorenbos, C.J.M.; Van Steijn, J.; Van Walderveen, P.E.; Van der Hooft, C. Nutritional status of community-dwelling elderly with newly diagnosed alzheimer’s disease: Prevalence of malnutrition and the relation of various factors to nutritional status. *J. Nutr. Health Aging* 2013, 17, 606–610. [CrossRef] [PubMed]

2. Gillioz, A.S.; Villars, H.; Voisin, T.; Cortes, F.; Gillette-Guyonnet, S.; Andrieu, S.; Gardette, V.; Nourhashemi, F.; Ousset, P.J.; Jouanny, P.; et al. Spared and impaired abilities in community-dwelling patients entering the severe stage of Alzheimer’s disease. *Dement. Geriatr. Cogn. Disord.* 2009, 28, 427–432. [CrossRef] [PubMed]

3. Galesi, L.F.; Leandro-Merhi, V.A.; de Oliveira, M.R. Association between indicators of dementia and nutritional status in institutionalised older people. *Int. J. Older People Nurs.* 2013, 8, 236–243. [CrossRef] [PubMed]
4. Malara, A.; Sgro, G.; Caruso, C.; Ceravolo, F.; Curinga, G.; Renda, G.F.; Spada, F.; Garo, M.; Rispoli, V. Relationship between cognitive impairment and nutritional assessment on functional status in Calabrian long-term-care. *Clin. Intero. Aging* **2014**, *9*, 105–110. [PubMed]

5. Droogsma, E.; van Asselt, D.; van Steijn, J.; Veeger, N.; van Dusseldorp, I.; De Deyn, P.P. Nutritional interventions in community-dwelling Alzheimer patients with (risk of) undernutrition: A systematic review. *Int. Psychogeriatr.* **2014**, *26*, 1–9. [CrossRef]

6. Barrett-Connor, E.; Edelstein, S.L.; Corey-Bloom, J.; Wiederholt, W.C. Weight loss precedes dementia in community-dwelling older adults. *J. Am. Geriatr. Soc.* **1996**, *44*, 1147–1152. [CrossRef] [PubMed]

7. Lauque, S.; Arnaud-Battandier, F.; Gillette-Guyonnet, S.; Plaze, J.M.; Andrieu, S.; Cantet, C.; Vellas, B. Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer’s disease at risk of malnutrition: A prospective randomized study. *J. Am. Geriatr. Soc.* **2004**, *52*, 1702–1707. [CrossRef] [PubMed]

8. Isaia, G.; Mondino, S.; Germinara, C.; Cappa, G.; Aimomino-Ricauda, N.; Bo, M.; Isaia, G.C.; Nobili, G.; Massaia, M. Malnutrition in an elderly demented population living at home. *Arch. Gerontol. Geriatr.* **2011**, *53*, 249–251. [CrossRef]

9. Cova, I.; Pomati, S.; Maggiore, L.; Forcella, M.; Cucumo, V.; Ghiretti, R.; Grande, G.; Muzzio, F.; Mariani, C. Nutritional status and body composition by bioelectrical impedance vector analysis: A cross sectional study in mild cognitive impairment and Alzheimer’s disease. *PLoS ONE* **2017**, *12*, e0171331. [CrossRef]

10. Besser, L.M.; Gill, D.P.; Monsell, S.E.; Brenowitz, W.; Meranus, D.H.; Ku, W.; Gustafson, D. Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer disease. *Alzheimer Dis. Assoc. Disord.* **2014**, *28*, 36–43. [CrossRef]

11. Stewart, R.; Masaki, K.; Xue, Q.L.; Peila, R.; Petrovitch, H.; White, L.R.; Launer, L.J. A 32-year prospective study of change in body weight and incident dementia: The Honolulu-Asia aging study. *Arch. Neurol.* **2005**, *62*, 55–60. [CrossRef]

12. Alhurani, R.E.; Vassilaki, M.; Aakre, J.A.; Mielke, M.M.; Kremers, W.K.; Machulda, M.M.; Geda, Y.E.; Knopman, D.S.; Peterson, R.C.; Roberts, R.O. Decline in weight and incident mild cognitive impairment: Mayo clinic study of aging. *JAMA Neurol.* **2016**, *73*, 439–446. [CrossRef] [PubMed]

13. Tamura, B.K.; Bell, C.L.; Masaki, K.H.; Amella, E.J. Factors associated with weight loss, low BMI, and malnutrition among nursing home patients: A systematic review of the literature. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 649–655. [CrossRef] [PubMed]

14. Chang, C.C.; Roberts, B.L. Feeding difficulty in older adults with dementia. *J. Clin. Nurs.* **2008**, *17*, 2266–2274. [CrossRef] [PubMed]

15. De Wilde, M.C.; Vellas, B.; Girault, E.; Yavuz, A.C.; Sijben, J.W. Lower brain and blood nutrient status in Alzheimer’s disease: Results from meta-analyses. *Alzheimers Dement. (New York)* **2017**, *3*, 416–431. [CrossRef] [PubMed]

16. Blennow, K.; Hampel, H. CSF markers for incipient Alzheimer’s disease. *Lancet Neurol.* **2003**, *2*, 605–613. [CrossRef]

17. Folstein, M.; Folstein, S.; McHugh, P. “Mini-mental state” a practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* **1975**, *12*, 189–198. [CrossRef]

18. Van der Flier, W.M.; Pijnenburg, Y.A.; Prins, N.; Lemstra, A.W.; Bouwman, F.H.; Teunissen, C.E.; van Berckel, B.N.; Stam, C.J.; Barkhof, F.; Visser, P.; et al. Optimizing patient care and research: The Amsterdam Dementia Cohort. *J. Alzheimers Dis.* **2014**, *41*, 313–327. [CrossRef]

19. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R., Jr.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers Dement.* **2011**, *7*, 263–269. [CrossRef]

20. Albert, M.S.; DeKosky, S.T.; Dickson, D.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gamst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers Dement.* **2011**, *7*, 270–279. [CrossRef]

21. Verhage, F. Intelligence and age in a Dutch sample. *Hum. Dev.* **1965**, *8*, 238–245. [CrossRef]

22. Stirban, A.; Heinemann, L. Skin autofluorescence a non-invasive measurement for assessing cardiovascular risk and risk of diabetes. *Eur. Endocrinol.* **2014**, *10*, 106–110. [CrossRef] [PubMed]
23. Van Harten, A.C.; Jongbloed, W.; Teunissen, C.E.; Scheltens, P.; Veerhuis, R.; van der Flier, W.M. CSF ApoE predicts clinical progression in nondemented APOEpsilon4 carriers. *Neurobiol. Aging* 2017, 57, 186–194. [CrossRef]

24. World Health Organization. *Waist Circumference and Waist-Hip Ratio;* WHO: Geneva, Switzerland, 2008.

25. Kyle, U.G.; Genton, L.; Karsegard, L.; Slosman, D.O.; Pichard, C. Single prediction equation for bioelectrical impedance analysis in adults aged 20–94 years. *Nutrition* 2001, 17, 248–253. [CrossRef]

26. Vellas, B.; Villars, H.; Abellani, G.; Soto, M.; Rolland, Y.; Guigoz, Y.; Morley, J.; Chumlea, W.; Salva, A.; Rubenstein, L.; et al. Overview of the MNA—Its history and challenges. *J. Nutr. Health Aging* 2006, 10, 456–465. [PubMed]

27. Vellas, B.; Guigoz, Y.; Garry, P.; Bennahum, D.; Lauque, S.; Albarède, J. The mini nutritional assessment (MNA) and its use in grading the nutritional state of elderly patients. *Appl. Nutr. Investig.* 1999, 15, 116–122. [CrossRef]

28. Guigoz, Y. The Mini Nutritional Assessment (MNA) review of the literature—What does it tell us? *J. Nutr. Health Aging* 2006, 10, 466–485. [PubMed]

29. Lindeboom, J.; Schmand, B.; Tulner, L.; Walstra, G.; Jonker, C. Visual association test to detect early dementia. *Clin. Chem.* 2001, 47, 1521–1525. [CrossRef] [PubMed]

30. Rey, A. *L’Examen Clinique en Psychologie;* The clinical psychological examination; Presses Universitaires de France: Paris, France, 1964.

31. Reitan, R. The relation of the trail making test to organic brain damage. *J. Consult. Psychol.* 1955, 19, 393–394. [CrossRef]

32. Wechsler, D. *Adult Intelligence Scale—Administration and Scoring Manual;* The Psychological Corporation: San Antonio, TX, USA, 1997.

33. Stroop, R. Studies of interference in serial verbal reactions. *J. Exp. Psychol.* 1935, 18, 643–662. [CrossRef]

34. Hughes, B. Missile wounds of the brain: A study of psychological deficits. *J. Neurol. Neurosurg. Psychiatry* 2002, 73, 126–133. [CrossRef] [PubMed]

35. Dubois, B.; Slachevsky, A.; Litvan, I.; Pillon, B. The FAB a frontal assessment battery at bedside. *Neurology* 2000, 55, 1621–1626. [CrossRef]

36. Benton, A.L. Differential behavioral effects in frontal lobe disease. *Neuropsychologia* 1967, 6, 53–60. [CrossRef]

37. Warrington, E.K.; James, M. *The Visual Object and Space Perception Battery; VOSP;* Pearson: London, UK, 1991.

38. Benton, A.L.; Dror, H.; Benet, C.; Hecquet, J.; Bonne, N.; de Visser, G.; De Camilli, P.; Hulette, C.; Scheltens, P.; Teunissen, C.E. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-beta 1-42 analysis results. *Clin. Chem.* 2018, 64, 576–585. [CrossRef] [PubMed]

39. 76, 15, 551. [CrossRef]

40. Agarwal, E.; Miller, M.; Yaxley, A.; Isenring, E. Malnutrition in the elderly: A narrative review. *Maturitas* 2013, 76, 296–302. [CrossRef] [PubMed]

41. Toledo, J.B.; Arnold, M.; Kastenmüller, G.; Chang, R.; Baillie, R.A.; Han, X.; Thambisetty, M.; Tenenbaum, J.D.; Suhre, K.; Thompson, J.W.; et al. Metabolic network failures in Alzheimer’s disease: A biochemical road map. *Alzheimers Dement.* 2017, 13, 965–984. [CrossRef]
47. Pistollato, F.; Sumalla Cano, S.; Elio, I.; Masias Vergara, M.; Giampieri, F.; Battino, M. Role of gut microbiota and nutrients in amyloid formation and pathogenesis of Alzheimer disease. *Nutr. Rev.* 2016, 74, 624–634. [CrossRef] [PubMed]

48. Bhattacharjee, S.; Lukiw, W.J. Alzheimer’s disease and the microbiome. *Front. Cell. Neurosci.* 2013, 7, 153. [CrossRef] [PubMed]

49. Buckley, R.F.; Maruff, P.; Ames, D.; Bourgeat, P.; Martins, R.N.; Masters, C.L.; Rainey-Smith, S.; Lautenschlager, N.; Rowe, C.C.; Savage, G.; et al. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer’s disease. *Alzheimers Dement.* 2016, 12, 796–804. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).